Several peptides can stimulate your pituitary gland to produce more human growth hormone (HGH). They fall into two main categories: GHRH analogs, which mimic your body’s natural growth hormone-releasing hormone, and GHRPs (growth hormone-releasing peptides), which trigger GH release through a completely different receptor. Understanding the distinction matters because these two classes work through separate signaling pathways and can even be combined for a stronger effect.
Two Pathways, Two Peptide Classes
Your pituitary gland has two distinct “switches” for releasing growth hormone. GHRH analogs flip the first switch by activating the same receptor your body’s own releasing hormone uses. GHRPs flip the second switch by binding to the ghrelin receptor, sometimes called the growth hormone secretagogue receptor. Because these pathways are independent, combining a peptide from each class produces a synergistic response, meaning the resulting GH pulse is larger than what either peptide would produce alone. Research on ovine pituitary cells confirmed that combined GHRH and GHRP-2 treatment increased both GH gene expression and GH release in a time-dependent manner beyond what either peptide achieved individually.
GHRH Analogs
Sermorelin
Sermorelin is a truncated version of your body’s natural GHRH, containing just the first 29 amino acids needed to activate the receptor. It was originally marketed for children with growth delays and is now used in age-management settings. Because it works through the same feedback loops as natural GHRH, your pituitary still regulates the total amount of GH produced, making it harder to push levels into an abnormal range. Research published in Clinical Interventions in Aging suggests that sermorelin may help preserve pituitary function during aging, potentially slowing the broader decline in hormone output that occurs over time. Its half-life is short, roughly 30 minutes, which produces a brief, natural-feeling GH pulse.
CJC-1295 (With and Without DAC)
CJC-1295 is a modified version of the same 29-amino-acid GHRH fragment, engineered for a longer life in the bloodstream. It comes in two forms that behave very differently. The version without DAC (sometimes called Modified GRF 1-29) has a half-life of about 30 minutes, similar to sermorelin, and produces short GH pulses. The version with DAC (Drug Affinity Complex) binds to albumin in your blood, extending its half-life to roughly 8 days. That means sustained GH elevation rather than distinct pulses. Many practitioners consider the shorter-acting version more physiologically natural because it mimics the pulsatile pattern your body uses on its own.
Tesamorelin
Tesamorelin is the only GHRH analog with full FDA approval, specifically for reducing excess abdominal fat in people with HIV-associated lipodystrophy. In a randomized clinical trial, tesamorelin reduced visceral fat by about 10% compared to a 6.6% increase in the placebo group, a net treatment effect of roughly 17%. It works the same way as other GHRH analogs but has the most robust clinical data behind it.
Growth Hormone-Releasing Peptides (GHRPs)
Ipamorelin
Ipamorelin stands out from other GHRPs because of its selectivity. Most GHRPs stimulate not only growth hormone but also cortisol (a stress hormone) and ACTH. Ipamorelin does not. In animal studies, it failed to raise ACTH or cortisol even at doses more than 200 times the amount needed to trigger GH release. That makes its hormonal profile closer to natural GHRH stimulation than any other GHRP tested, which is why it’s often described as the first truly selective growth hormone secretagogue.
GHRP-2 and GHRP-6
GHRP-2 and GHRP-6 are older peptides that reliably boost GH output but come with broader hormonal effects. Both raise cortisol and ACTH levels alongside growth hormone. GHRP-6 is also known for strongly increasing appetite through ghrelin-pathway activation, which can be a benefit or a drawback depending on your goals. GHRP-2 stimulates GH secretion through the PKC signaling pathway, which is entirely separate from the cAMP pathway used by GHRH, confirming that these two peptide classes act on different receptors even at the molecular level.
MK-677 (Ibutamoren): The Oral Option
MK-677, also called ibutamoren, is not technically a peptide. It’s a small molecule that activates the same ghrelin receptor as GHRPs, but it can be taken by mouth. In a study published in The Journal of Clinical Endocrinology & Metabolism, MK-677 raised IGF-1 levels (a downstream marker of growth hormone activity) to an average of 264 ng/mL compared to 188 ng/mL in the placebo group during a calorie-restricted period. It also reversed the catabolic effects of dieting. Its oral availability makes it appealing, but it carries notable risks: a clinical trial in hip fracture patients was terminated early due to a safety signal for congestive heart failure.
Why Timing and Fasting Matter
The conditions under which you use any GH-stimulating peptide can significantly affect the result. Your nutritional state is one of the strongest natural modulators of growth hormone release. A study in The Journal of Clinical Investigation found that a five-day fast nearly tripled 24-hour integrated GH concentrations, increased pulse frequency from about 6 to 10 pulses per day, and doubled maximum pulse amplitude. You don’t need to fast for five days to benefit from this principle, but it explains why most peptide protocols call for administration on an empty stomach, typically at least two hours after eating. Food, particularly carbohydrates and fats, blunts GH release in unpredictable ways.
Most users administer GH peptides before bed to coincide with the body’s largest natural GH pulse, which occurs during deep sleep. Others split doses between morning (fasted) and bedtime to create multiple daily pulses.
Side Effects of Peptide-Driven GH Elevation
Because these peptides raise actual growth hormone levels, they share many of the same side effects as GH itself. The most clinically relevant is the effect on blood sugar. Growth hormone is a counter-regulatory hormone to insulin, meaning it pushes blood glucose up. Studies on GH replacement show that fasting glucose and insulin levels typically rise in the first six months of treatment but often normalize after one to two years at moderate doses. At high doses or in people who are already obese or older, the risk of sustained insulin resistance increases.
Water retention, joint stiffness, and tingling in the hands are common early effects that usually diminish over weeks. GHRP-6 and MK-677 can cause significant hunger spikes. GHRP-2 and GHRP-6 can elevate cortisol, which is worth considering if stress-related symptoms are already a concern.
Regulatory Status in the United States
The FDA has moved aggressively to restrict compounded versions of most GH-stimulating peptides. In September 2023, the agency placed GHRP-2, GHRP-6, ipamorelin, and ibutamoren on its Category 2 list for compounding, citing safety concerns including immunogenicity risks from peptide impurities, effects on blood glucose, and in the case of ibutamoren, the heart failure signal mentioned above. This means compounding pharmacies face significant restrictions on producing these substances. Tesamorelin remains available as an FDA-approved pharmaceutical product. Sermorelin and CJC-1295 without DAC have had a more complicated regulatory path but have historically been available through compounding pharmacies, though the landscape continues to shift.
The practical effect of these restrictions is that obtaining many of these peptides legally now requires navigating a narrower set of options, and products sold through unregulated channels carry real risks of contamination, mislabeling, or incorrect dosing.